Evidence-Based Complementary and Alternative Medicine / 2022 / Article / Tab 1 / Review Article
Effectiveness of Combined Thrombolysis and Mild Hypothermia Therapy in Acute Cerebral Infarction: A Meta-Analysis Study (published year) Study type Country Sex (M/F) Females (%) Age (years) (mean ± SD) Duration (hours) Initial NIHSS Follow-up (days) Bi (2011) [23 ] RCT China T: 10/21 T: 32.3 T: 68.45 ± 6.89 T: 2.5 ± 1 T: 11.4 ± 2.8 90 C: 13/18 C: 58.1 C: 68.55 ± 6.28 C: 2.5 ± 1 C: 11.0 ± 2.7 Patrick (2017) [24 ] RCT America T: 34/29 T: 46 T: 65.5 ± 10.3 T: 2.0 ± 0.5 T: 14.1 ± 4.8 90 C: 35/22 C: 39 C: 67.5 ± 11.1 C: 2.15 ± 0.5 C: 14.5 ± 4.9 Katja (2014) [25 ] RCT Australia T: 12/6 T: 33 T: 70 — T: 11 90 C: 8/10 C: 56 C: 66 C: 14 Ovesen (2013) [26 ] RCT Denmark T: 9/8 T: 47.1 T: 62.3 T: 1.68 T: 8 90 C: 8/6 C: 42.9 C: 65.9 C: 3.74 C: 9 De (2004) [27 ] RCT America T: 13/5 T: 28 T: 60.9 ± 12.1 T: 3.0 ± 0.5 T: 15.2 ± 4.4 37 C: 6/16 C: 71 C: 67.3 ± 12.5 C: 4.0 ± 0.25 C: 14.6 ± 5.6 Derk (2001) [28 ] RCT America T: 5/5 T: 50 T: 71.1 ± 14.3 T: 3.1 ± 1.4 19.86 ± 3.3 90 C: 5/4 C: 44 C: 68.2 ± 12.3 C: 4.4 ± 1.7 Hong (2014) [18 ] RCT South Korea T: 23/16 T: 41 T: 64.5 ± 17.0 <5 T: 16 90 C: 18/18 C: 64 C: 68.1 ± 13.3 C: 17 Thomas (2010) [29 ] RCT California T: 24 45 65.5 ± 12.1 <6 14.0 ± 5.0 90 C: 24 H Bart (2019) [17 ] RCT Netherlands T: 28/21 T: 37 T: 69.6 <6 T: 11 91 C: 27/22 C: 39 C: 71.1 C: 11 Cui (2020) [30 ] RCT China T: 26/15 T: 37 T: 55.16 ± 6.57 2.48 ± 0.60 — 14 C: 25/16 C: 39 C: 55.29 ± 6.65 Li (2018) [31 ] RCT China T: 28 — 62.6 ± 5.1 <4.5 T: 15.75 ± 6.43 14 C: 16.15 ± 4.06 C: 22 Yang (2020) [32 ] RCT China T: 23/17 T: 37 T: 64.5 ± 12.3 T: 3.5 ± 0.3 T: 8.1 ± 3.2 7 C: 25/15 C: 39 C: 62.1 ± 13.9 C: 3.2 ± 0.2 C: 8.2 ± 2.7 Jin (2017) [33 ] RCT China T: 45 — — — — 30 C: 45 Wang (2018) [34 ] RCT China T: 28/25 T: 37 T: 51.29 ± 9.14 T: 3.29 ± 0.81 T: 15.47 ± 3.89 — C: 29/24 C: 39 C: 52.08 ± 8.62 C: 3.70 ± 0.97 C: 15.83 ± 6.57 Li (2014) [35 ] RCT China T: 16/6 T: 37 T: 65.48 ± 7.66 <3 T: 17.4 ± 3.8 30 C: 14/8 C: 39 C: 63.24 ± 7.74 C: 16.6 ± 6.2 Wang (2018) [36 ] RCT China T: 51/49 T: 37 T: 55.2 ± 1.2 T: 1.50 ± 1.10 T: 16.23 ± 1.56 — C: 58/42 C: 39 C: 53.7 ± 1.5 C: 1.30 ± 0.60 C: 16.23 ± 1.31 Sun (2018) [37 ] RCT China T: 10/15 T: 58 T: 64.25 ± 10.47 T: 3.14 ± 0.55 T: 15.89 ± 7.08 7 C: 12/13 C: 52 C: 62.14 ± 9.35 C: 3.09 ± 0.71 C: 15.69 ± 6.39 Pei (2018) [38 ] RCT China T: 23/17 T: 37 T: 61.11 ± 7.31 T: 3.29 ± 0.81 T: 16.33 ± 5.67 7 C: 23/17 C: 39 C: 61.47 ± 7.02 C: 3.70 ± 0.97 C: 16.85 ± 5.31 Hu (2016) [39 ] RCT China T: 31 — 60.18 ± 10.18 3.56 ± 0.79 T: 15.22 ± 7.57 90 C: 29 C: 15.74 ± 6.42 Cai (2020) [40 ] RCT China T: 60 — 61.3 ± 4.1 3.65 ± 0.64 T: 12.03 ± 2.56 7 C: 34 C: 12.01 ± 2.45 Zhao (2018) [41 ] RCT China T: 18/15 T: 37 T: 60.33 ± 6.29 — T: 14.78 ± 3.01 45 C: 17/16 C: 39 C: 61.24 ± 6.44 C: 14.23 ± 2.28 Wei (2020) [42 ] RCT China T: 27/21 T: 37 T: 64.5 ± 9.4 T: 2.80 ± 1.00 T: 14.2 ± 3.7 28 C: 30/19 C: 39 C: 63.8 ± 10.2 C: 2.70 ± 1.20 C: 13.9 ± 3.0 Yang (2020) [43 ] RCT China T: 35/33 T: 37 T: 62.43 ± 12.06 <4.5 — — C: 36/32 C: 39 C: 62.75 ± 11.82 Ma (2017) [44 ] RCT China T: 8/7 T: 37 T: 66.33 ± 9.81 T: 4.66 ± 0.54 — — C: 7/8 C: 39 C: 68.26 ± 9.53 C: 4.81 ± 0.35 Zhu (2019) [45 ] RCT China T: 19/14 T: 37 T: 64 ± 13 <4.5 T: 23.7 ± 2.2 — C: 17/16 C: 39 C: 62 ± 13 C: 24.3 ± 3.2 Liu (2019) [46 ] RCT China T: 28/38 T: 37 T: 64.26 ± 10.46 T: 3.08 ± 0.72 — — C: 32/34 C: 39 C: 62.13 ± 9.36 C: 3.13 ± 0.56 Zhang (2021) [47 ] RCT China T: 25/16 T: 39 T: 59.6 ± 3.2 T: 3.47 ± 0.5 T: 12.01 ± 2.65 7 C: 25/13 C: 34 C: 60.5 ± 3.3 C: 3.52 ± 0.48 C: 12.02 ± 2.47
T, treatment group; C, control group; Age and initial NIHSS shown as median values. “—” indicates data not specified RCT randomized controlled trial, NIHSS National Institutes of Health Stroke Scale.
